Connect with us

International

Treatment improves cognition in Down Syndrome patients

AFP

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the “promising” results may raise hopes of improving patients’ quality of life.

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

“The experiment is very satisfactory, even if we remain cautious,” said Nelly Pitteloud of Switzerland’s Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Advertisement
20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL
previous arrow
next arrow

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are “particularly important”, the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

“We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome,” said Vincent Prevot, study co-author and head of neuroscience research at France’s INSERM institute. 

– Mice research –

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

Advertisement
20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL
previous arrow
next arrow

They then demonstrated that cognitive deficiencies — as well as loss of smell, a common symptom of Down Syndrome — were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through  their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone’s frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Advertisement
20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL
previous arrow
next arrow

Six of the seven men showed improvement in cognition with no significant side effects — however none showed a change in their sense of smell.

“We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention,” Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

– ‘Improve quality of life’ –

The authors acknowledged some limitations of the study, including its size and that the choice of patients was “pushed by their parents”.

“The clinical trial only focused on seven male patients — we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome,” Pitteloud said.

Advertisement
20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL
previous arrow
next arrow

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

“We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life,” Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the “tour de force study”.

He told AFP that while it is “difficult to envision” how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer’s disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

Advertisement
20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL
previous arrow
next arrow

“For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone.”

Continue Reading
Advertisement
20250701_dengue_300x250_01
20250701_dengue_300x250_02
20250715_donacion_sangre_central_300x250
20250701_vacunacion-influenza-300x250
20250701_vacunacion_vph-300x250
20250501_mh_noexigencia_dui_300x250
20231124_etesal_300x250_1
20230601_agenda_primera_infancia_300X250
MARN1

International

Brésil : 11 morts et 45 blessés dans un violent accident entre un bus et un camion

Onze personnes ont perdu la vie et quarante-cinq autres ont été blessées lors d’une collision frontale entre un camion de marchandises et un autobus dans le centre-ouest du Brésil, ont annoncé les autorités ce samedi.

L’accident s’est produit vendredi à 21h40, heure locale, sur la route BR-163, près de la localité de Lucas do Rio Verde, dans l’État du Mato Grosso.

Selon la Police routière fédérale (PRF), un autobus reliant la capitale de l’État, Cuiabá, à Sinop est entré en collision frontale avec un camion transportant des graines de coton.

« L’accident a fait 11 morts », a indiqué la PRF dans un communiqué, précisant qu’une enquête est en cours pour déterminer les causes du drame.

Les blessés ont été transportés vers des hôpitaux de la région : 11 sont dans un état grave, 26 présentent des blessures modérées et 8 sont légèrement touchés, selon la police routière.

Advertisement

20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL

previous arrow
next arrow

Le conducteur du camion a subi des blessures modérées.

La société de transport Rio Novo, propriétaire de l’autobus, a confirmé l’accident.
« Notre priorité est de prendre soin des victimes et de leurs familles », a déclaré l’entreprise dans un message publié sur les réseaux sociaux.

Les accidents mortels sont fréquents sur les routes brésiliennes, un pays aux dimensions continentales.

Dimanche dernier, huit personnes avaient trouvé la mort dans une collision impliquant deux voitures et une moto dans l’État de Minas Gerais (sud-est).

En mai, une collision frontale entre une minifourgonnette et un camion avait fait neuf morts et dix blessés, également dans le Minas Gerais.

Advertisement

20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL

previous arrow
next arrow

Continue Reading

International

U.S. doubles bounty on Venezuela’s Nicolás Maduro to $50 million

In February, the United States designated eight Latin American criminal organizations as “global terrorist” groups, including Mexico’s Sinaloa Cartel, Venezuela’s Tren de Aragua, and the MS-13 gang. In July, it added the Cartel of the Suns to the list — a group Washington claims is led by Venezuelan President Nicolás Maduro.

Last Thursday, U.S. President Donald Trump’s administration doubled the reward for information leading to Maduro’s arrest, raising it from $25 million to $50 million, U.S. Attorney General Pam Bondi announced on social media platform X.

U.S. Secretary of State Marco Rubio explained that labeling the Cartel of the Suns as a terrorist organization allows for a strategic shift in dealing with the Venezuelan regime, as it is now also considered a direct threat to U.S. national security, according to El Espectador.

In an interview with The World Over on EWTN, Rubio said the designation enables the U.S. to “use intelligence agencies, the Department of Defense, or any other element of American power to go after them.” He stressed this is no longer just a law enforcement matter, but a national security operation.

When asked at the White House whether he believes it is worth sending the military to combat Latin American drug cartels, Trump responded:
“Latin America has many cartels, a lot of drug trafficking, so, you know, we want to protect our country. We have to protect it.”

Advertisement

20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL

previous arrow
next arrow

Continue Reading

International

Three injured in early-morning New York City shooting

A shooting in New York City early Saturday morning left three people injured, a police spokesperson told AFP.

The incident occurred at around 1:20 a.m. local time (05:20 GMT) following a dispute. An 18-year-old woman sustained a scratch to the neck, while a 19-year-old man and a 65-year-old man were injured in the lower limbs.

The victims were taken to Bellevue Hospital, where they were reported to be in stable condition.

The alleged shooter was taken into custody at the scene, and a firearm was recovered. As of now, the suspect has not been formally charged.

Videos circulating on social media show scenes of panic among the crowd, though AFP has not been able to verify their authenticity. The incident comes just weeks after another shooting in a Manhattan skyscraper that left four people injured before the gunman took his own life.

Advertisement

20250701_dengue_728x90
20250715_donacion_sangre_central_728x90
20250701_vacunacion-influenza-728x90
20250701_vacunacion_vph-728x90
20250501_mh_noexigencia_dui_728x90
20231124_etesal_728x90_1
20230601_agenda_primera_infancia_728X90
domfuturo_netview-728x90
20240604_dom_728x90
CEL

previous arrow
next arrow

Continue Reading

Trending

Central News